Immunotherapy Now First Line for Esophageal Cancer Immunotherapy Now First Line for Esophageal Cancer
Nivolumab (Opdivo) with chemotherapy or in combination with ipilimumab (Yervoy) has been approved by the FDA for first-line use in the treatment of unresectable advanced or metastatic esophageal cancer.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Esophagus Cancer | Health | Hematology | Immunotherapy | Yervoy